PaxVax is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the pediatric, travel, endemic and respiratory fields.
VIVOTIF® (Typhoid Vaccine Live Oral Ty21a)
Type of Vaccine: Live, attenuated bacteria (Ty21a strain)
Vivotif® is a live attenuated typhoid fever vaccine for oral administration. It is the only oral vaccine indicated for use against Salmonella typhi, the most prevalent of the typhoid fever-causing bacteria. The vaccine is indicated for adults and children over the age of five and has an excellent track record for safety, having been on the market for more than 20 years. It is currently licensed in over 30 countries, including in the USA. Recent results suggest that Vivotif® may be unique in also protecting against S. paratyphi, a similar but milder variant of typhoid.